Compare iShares MSCI Germany (DAX) (EWG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs BIO-TECHNE Corp — how do they compare? iShares MSCI Germany (DAX) trades at $41.98 (market cap $1.44B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 7.9× iShares MSCI Germany (DAX)'s market cap, and BIO-TECHNE Corp pays a 0.44% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 56 Days and BIO-TECHNE Corp for 63 Days on average.
| EWG | TECH | |
|---|---|---|
Market Cap | $1.44B | $11.37B |
Volume | 1,258,794 | 3,153,511 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $72.61 |
52-Week Low | $38.08 | $43.31 |
Typical Hold Time | 56 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG is trading at $40.91, down 1.4% today amid bearish technical signals with 19 sell indicators versus 1 buy. The stock faces resistance at $41 with support at $40, while European market sentiment remains cautious due to ECB rate hike expectations and energy price pressures. Key financial ratios are unavailable in the current dataset.
The outlook remains cautious with technical indicators signaling bearish momentum and European macroeconomic headwinds from potential ECB tightening. Investment opportunities depend on resolution of energy inflation concerns, while risks include further rate hikes and deteriorating eurozone business confidence.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
